Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

nalbuphine

A synthetic mixed opioid agonist-antagonist with analgesic properties. Although its exact mechanism has not been fully delineated, it is hypothesized that upon administration, nalbuphine binds to kappa receptors in the central nervous system (CNS), thereby inhibiting the release of neurotransmitters that mediate pain, such as substance P. Additionally, nalbuphine exerts post-synaptic inhibitory effects on interneurons and output neurons of the spinothalamic tract, responsible for transporting nociceptive information. Compared to other opioid agents that stimulate mu receptors, nalbuphine antagonizes mu receptors, thereby potentially producing less intense respiratory depression.
Search NCI's Drug Dictionary